

Supplementary Table S10**Patient characteristics by ER status in the Stockholm cohort (n= 159)**

Characteristic	ER positive n (%)	ER negative n (%)
	130 (82)	29 (18)
PR		
Positive	108 (83)	6 (21)
Negative	22 (17)	23 (79)
Mean age	54	59
Tumour size		
<20 mm	51 (40)	13 (46)
≥20 mm	78 (60)	15 (54)
Missing cases: 2		
Elston grade		
I	28 (23)	0 (0)
II	53 (43)	5 (20)
III	41 (34)	20 (80)
Missing cases: 12		
Nodal status		
Negative	73 (58)	21 (72)
Positive	52 (42)	8 (28)
Missing cases: 5		
Systemic adjuvant therapy*		
None	17 (13)	16 (55)
Endocrine	87 (67)	9 (31)
Chemotherapy	8 (6)	4 (14)
Both	18 (14)	0 (0)
Ki67		
<8%	39 (41)	3 (16)
≥8%	55 (59)	16 (84)
Missing cases: 46		
PAM50 subtype		
Basal	5 (4)	14 (48)
<i>ERBB2</i>	12 (9)	6 (21)
Luminal A	51 (39)	1 (4)
Luminal B	45 (35)	3 (10)
Normal-like	17 (13)	5 (17)

*Endocrine or Chemotherapy refers to each treatment alone or in combination with radiotherapy, Both refers to a combination of endocrine treatment and chemotherapy.

